| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8274208 | Journal of the Neurological Sciences | 2016 | 4 Pages |
Abstract
Fingolimod is able to improve visual and somatosensory evoked potential in RR-MS patients even if clinical disability scale remains stable. VEP and SEP could give eloquent information on pathway underweighted in EDSS. EPs are useful to evaluate fingolimod effects in clinical practice.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
R. Iodice, A. Carotenuto, R. Dubbioso, I. Cerillo, L. Santoro, F. Manganelli,